The content on this site is intended for healthcare professionals only
Dr Kumar presents findings during a press conference on phase I study of MLN9708, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma at the 2012 ASH Annual Meeting in Atlanta, Georgia.